Alzheimer s DiseaseReactVRNCT07620509
Usefulness of a Virtual Response Test as a Predictor of Functional and Cognitive Abilities in Older Adults With Different Degrees of Cognitive Impairment: a Pilot Study (ReactVR)
A study testing Virtual reality reaction time test in people with Alzheimer s Disease and Dementia, run by University of Vigo at 1 site in Spain.
Trial summary
1. BACKGROUND Population aging is one of the most significant trends of the 21st century.In 2020, 21% of the European population was 65 years of age or older, compared to 16% in 2001.Today, 1 in 9 people is over 60, but it is estimated that by 2050, this will be 1 in 5. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Alzheimer s Disease, Dementia, Virtual Reality
- What is being tested?
- Virtual reality reaction time test
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSpain
- Study dates
- 25 May 2026to 26 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- age ≥65 years
- membership in a patient association with cognitive impairment
- signed informed consent
Who cannot join
- cardiovascular, pulmonary or musculoskeletal pathology that limits the evaluation
- inability to understand instructions
- severe sensory impairment, vertigo, epilepsy or uncontrolled psychosis
Trial locations and contacts
1 site in 1 country.
About this study
- BACKGROUND Population aging is one of the most significant trends of the 21st century.In 2020, 21% of the European population was 65 years of age or older, compared to 16% in 2001.Today, 1 in 9 people is over 60, but it is estimated that by 2050, this will be 1 in 5. Therefore, population aging is a phenomenon that can no longer be ignored. In recent decades, the increase in the number of older people is due to the increase in life expectancy. By 2026, the average life expectancy for men is estimated at 77.65 years, and for women, values are projected to reach 85.5 years. Aging is generally associated with neuromuscular deterioration (such as sarcopenia), gait and balance disorders and loss of mobility. In general, a loss of functional independence. In the population over 60 years of age, approximately 3% of muscle strength is lost per year due to muscle denervation and the conversion of type II muscle fibers to type I muscle fibers, decreasing their muscle power for performing activities of daily living. This muscle weakness eventually leads to frailty in older adults, and, consequently, an increased rate of falls and fractures. Cognitive ability is also closely related to motor ability, since there are cognitive requirements for developing all physical functions and balance, and these can be altered when attention is diverted or reduced. Executive function and processing speed are some of the cognitive functions related to postural stability, which can be impaired in older adults with cognitive decline. Cognitive decline and dementia are geriatric syndromes with a fairly high incidence. Around 7% of those over 65 years of age are affected. affected, a percentage that increases to 50% for people over 80 years old, which means that more than 1.5 million people in Spain directly suffer from this condition. Furthermore, the risk of falls is linked to reaction times, which involve both cognitive and motor aspects (discussed above). These combine attention, perception, and information integration with the final motor response, as well as psychological and emotional factors such as fear of falling or insecurity. Currently, one in three adults over 65 and one in two adults over 80 fall each year, making it a serious public health problem among older adults, as falls lead to premature mortality, loss of independence, and admission to assisted living facilities. A widely used scale for predicting the risk of falls is the Time Up and Go (TUG) test. The patient is asked to stand up from a seated position, walk three meters, turn around, and return to the starting position while the time is measured. Patients who do not complete the test in less than 13.5 seconds are considered to have a high risk of falls. Although it is included in various clinical guidelines, the literature recommends identifying alternative tools that can more accurately identify patients at risk of falls, as several studies have shown that the accuracy of this test is limited. Within the TUG (Trauma Glide Test), we have the cognitive TUG (TUG-cog), which assesses the previous test but with the interference of a concurrent cognitive activity. In neurological processes, such as Alzheimer's disease, deficits in divided attention and the ability to perform dual tasks appear to be related to functional mobility impairments, directly linked to the risk of falls. Currently, there are also simple reaction time tests (SRTT), which consist of a computerized test to measure a person's reaction times by pressing a response button with the index finger of their dominant hand. However, there is controversy regarding the influence of motor disability on performance in the computerized SRTT task assessment, since the response depends on the ability to press a key with a finger. The use of virtual reality software could facilitate the measurement of reaction times in performing functional tasks-tasks that require greater upper limb mobility, which can be a key factor in preventing falls-without being limited to measuring the movement of a single finger.
- HYPOTHESES AND OBJECTIVES H0: Knowing the functional reaction times assessed with virtual reality does not help to understand the integrity of the physical, functional, and cognitive abilities of older adults with cognitive impairment, nor can it predict their risk of falling or their level of cognitive impairment.
- General Objective 1.1 To determine the feasibility of using a virtual reaction time test (VRTT) as a predictor of falls and the level of cognitive impairment in older adults with cognitive impairment.
- Specific Objectives 2.1 To analyze the relationship between the VRTT and the risk of falling as measured by the Timed Up and Go (TUG) Test. 2.2 Analyze the relationship between VRTT obtained in the virtual test and the level of cognitive impairment measured with the Cambridge Cognitive Examination (CAMCOG). 2.3 Estimate TUG and CAMCOG scores based on reaction times obtained in the VRTT
- Conditions
- Alzheimer s Disease, Dementia, Virtual Reality, Virtual Reality Cognitive Training, Reaction Time
- Being tested
- Virtual reality reaction time test
- Medical subject headings
- Dementia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual reality reaction time testOther
A measurement is taken using the Rezzil reaction time test (measured in milliseconds). This software comprises a collection of training games designed to improve physical and cognitive performance across a wide range of sports within an immersive virtual reality environment. In microwall mode, a 3x3 grid is presented, and the objective is to respond to a random stimulus projected onto it with a rapid limb movement, making several attempts over 45 seconds.
| Study group | Role | What they receive |
|---|---|---|
| Virtual reaction time test Group | Experimental | The intervention will consist of a single session measuring virtual reaction times using Rezill software Receives: Other: Virtual reality reaction time test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Virtual reality reaction time test
A measurement is taken using the Rezzil reaction time test (measured in milliseconds). This software comprises a collection of training games designed to improve physical and cognitive performance across a wide range of sports within an immersive virtual reality (VR) environment. In microwall mode, a 3x3 grid is presented, and the objective is to respond to a random stimulus projected onto it with a rapid limb movement, making several attempts over 45 seconds.
The average reaction time is recorded
Measured: Baseline
Secondary outcomes (3)
Level of cognitive impairment assessed using the Global Deterioration Scale (GDS)
GDS is is a 7-stage clinical assessment tool used to measure the progression of cognitive decline and dementia. The scale breaks down cognitive health into the following stages:
Stage 1: No Cognitive Decline. Stage 2: Very Mild Cognitive Decline. Stage 3: Mild Cognitive Decline. Stage 4: Moderate Cognitive Decline. Considered early dementia. Stage 5: Moderately Severe Cognitive Decline. Middle dementia stage. Stage 6: Severe Cognitive Decline. Dementia Stage 7: Very Severe Cognitive Decline. Late-stage dementia.
Measured: Baseline
Level of cognitive ability assessed using the Cambridge Cognitive Examination-Revised (CAMCOG-R) test
The CAMCOG-R is a comprehensive neuropsychological test designed to evaluate cognitive impairment and assist in diagnosing dementia. Total score ranges from 0 to 105 points, with higher scores indicating better cognitive function.
The CAMCOG-R thoroughly evaluates 8 core neurological and cognitive domains:Orientation (10 points): Measures awareness of time, date, and location.Language (30 points): Tests comprehension, naming, reading, writing, and verbal fluency.Memory (27 points): Assesses remote memory, recent memory, and learning ability (including delayed recall).Attention and Calculation (9 points): Evaluates working memory and arithmetic skills.Praxis (12 points): Tests motor planning through tasks like copying shapes or mimicking actions (e.g., folding paper).Abstraction (8 points): Measures problem-solving and the ability to understand similarities.Perception (9 points): Assesses visual perception and spatial recognition.Executive Function: Evaluates higher-order organization
Measured: Baseline
Gait functionality measured with the Timed Up and Go Test (TUG test)
The TUG test is a quick, functional assessment used by physical therapists and healthcare providers to measure a person's mobility, balance, and fall risk. The test records how long it takes to stand from a chair, walk 3 meters, turn, and sit back down. Results are evaluated based on the time taken to complete the task:
<10 Seconds: Normal, independent mobility. 10 to 12 Seconds: Indicates a moderate risk of falling. 12 to 14 Seconds: Indicates a high risk of falling. >20 Seconds: Poor functional mobility; often requires further assessment for outside mobility and assistive devices.
>30 Seconds: Indicates significant mobility impairment and dependency.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2026
- Study start25 May 2026
- Primary completion25 May 2026
- Study completion26 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer s DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Vigo
- Sponsor type
- University, hospital or other
- Collaborators
- The Association of Relatives of Alzheimer's Patients and Other Dementias of Galicia (Afaga Alzheimer)
- Responsible party
- Principal investigator, Pablo Campo-Prieto, University of Vigo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07620509
- Sponsor's protocol ID
- HEALTHYFIT-UVIGO 2/2026
- Acronym
- ReactVR
- Status last verified
- Apr 2026
- First submitted
- 26 May 2026
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Usefulness of a Virtual Response Test as a Predictor of Functional and Cognitive Abilities in Older Adults With Different Degrees of Cognitive Impairment: a Pilot Study (ReactVR)
- ClinicalTrials.gov ID
- NCT07620509
- Acronym / sponsor ID
- ReactVR / HEALTHYFIT-UVIGO 2/2026
- Conditions
- Alzheimer s Disease, Dementia, Virtual Reality, Virtual Reality Cognitive Training, Reaction Time
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University of VigoUniversity, hospital or other
- Collaborators
- The Association of Relatives of Alzheimer's Patients and Other Dementias of Galicia (Afaga Alzheimer)
- Study start
- 25 May 2026 (actual)
- Primary completion
- 25 May 2026 (actual)
- Study completion
- 26 May 2026 (actual)
- First posted
- 2 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- BACKGROUND Population aging is one of the most significant trends of the 21st century.In 2020, 21% of the European population was 65 years of age or older, compared to 16% in 2001.Today, 1 in 9 people is over 60, but it is estimated that by 2050, this will be 1 in 5. Therefore, population aging is a phenomenon that can no longer be ignored. In recent decades, the increase in the number of older people is due to the increase in life expectancy. By 2026, the average life expectancy for men is estimated at 77.65 years, and for women, values are projected to reach 85.5 years. Aging is generally associated with neuromuscular deterioration (such as sarcopenia), gait and balance disorders and loss of mobility. In general, a loss of functional independence. In the population over 60 years of age, approximately 3% of muscle strength is lost per year due to muscle denervation and the conversion of type II muscle fibers to type I muscle fibers, decreasing their muscle power for performing activities of daily living. This muscle weakness eventually leads to frailty in older adults, and, consequently, an increased rate of falls and fractures. Cognitive ability is also closely related to motor ability, since there are cognitive requirements for developing all physical functions and balance, and these can be altered when attention is diverted or reduced. Executive function and processing speed are some of the cognitive functions related to postural stability, which can be impaired in older adults with cognitive decline. Cognitive decline and dementia are geriatric syndromes with a fairly high incidence. Around 7% of those over 65 years of age are affected. affected, a percentage that increases to 50% for people over 80 years old, which means that more than 1.5 million people in Spain directly suffer from this condition. Furthermore, the risk of falls is linked to reaction times, which involve both cognitive and motor aspects (discussed above). These combine attention, perception, and information integration with the final motor response, as well as psychological and emotional factors such as fear of falling or insecurity. Currently, one in three adults over 65 and one in two adults over 80 fall each year, making it a serious public health problem among older adults, as falls lead to premature mortality, loss of independence, and admission to assisted living facilities. A widely used scale for predicting the risk of falls is the Time Up and Go (TUG) test. The patient is asked to stand up from a seated position, walk three meters, turn around, and return to the starting position while the time is measured. Patients who do not complete the test in less than 13.5 seconds are considered to have a high risk of falls. Although it is included in various clinical guidelines, the literature recommends identifying alternative tools that can more accurately identify patients at risk of falls, as several studies have shown that the accuracy of this test is limited. Within the TUG (Trauma Glide Test), we have the cognitive TUG (TUG-cog), which assesses the previous test but with the interference of a concurrent cognitive activity. In neurological processes, such as Alzheimer's disease, deficits in divided attention and the ability to perform dual tasks appear to be related to functional mobility impairments, directly linked to the risk of falls. Currently, there are also simple reaction time tests (SRTT), which consist of a computerized test to measure a person's reaction times by pressing a response button with the index finger of their dominant hand. However, there is controversy regarding the influence of motor disability on performance in the computerized SRTT task assessment, since the response depends on the ability to press a key with a finger. The use of virtual reality software could facilitate the measurement of reaction times in performing functional tasks-tasks that require greater upper limb mobility, which can be a key factor in preventing falls-without being limited to measuring the movement of a single finger.
- HYPOTHESES AND OBJECTIVES H0: Knowing the functional reaction times assessed with virtual reality does not help to understand the integrity of the physical, functional, and cognitive abilities of older adults with cognitive impairment, nor can it predict their risk of falling or their level of cognitive impairment.
- General Objective 1.1 To determine the feasibility of using a virtual reaction time test (VRTT) as a predictor of falls and the level of cognitive impairment in older adults with cognitive impairment.
- Specific Objectives 2.1 To analyze the relationship between the VRTT and the risk of falling as measured by the Timed Up and Go (TUG) Test. 2.2 Analyze the relationship between VRTT obtained in the virtual test and the level of cognitive impairment measured with the Cambridge Cognitive Examination (CAMCOG). 2.3 Estimate TUG and CAMCOG scores based on reaction times obtained in the VRTT
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Virtual reaction time test Group | Experimental | Other: Virtual reality reaction time testThe intervention will consist of a single session measuring virtual reaction times using Rezill software |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (3 listed)
- age ≥65 years
- membership in a patient association with cognitive impairment
- signed informed consent
Key exclusion criteria (3 listed)
- cardiovascular, pulmonary or musculoskeletal pathology that limits the evaluation
- inability to understand instructions
- severe sensory impairment, vertigo, epilepsy or uncontrolled psychosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Virtual reality reaction time testA measurement is taken using the Rezzil reaction time test (measured in milliseconds). This software comprises a collection of training games designed to improve physical and cognitive performance across a wide range of sports within an immersive virtual reality environment. In microwall mode, a 3x3 grid is presented, and the objective is to respond to a random stimulus projected onto it with a rapid limb movement, making several attempts over 45 seconds. | Other | Virtual reaction time test Group |
Primary outcome
Virtual reality reaction time test
Time frame: Baseline
A measurement is taken using the Rezzil reaction time test (measured in milliseconds). This software comprises a collection of training games designed to improve physical and cognitive performance across a wide range of sports within an immersive virtual reality (VR) environment. In microwall mode, a 3x3 grid is presented, and the objective is to respond to a random stimulus projected onto it with a rapid limb movement, making several attempts over 45 seconds. The average reaction time is recorded
3 secondary outcomes
Level of cognitive impairment assessed using the Global Deterioration Scale (GDS)
Time frame: Baseline
Level of cognitive ability assessed using the Cambridge Cognitive Examination-Revised (CAMCOG-R) test
Time frame: Baseline
Gait functionality measured with the Timed Up and Go Test (TUG test)
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Alzheimer s Disease
RecruitingObservational study
Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)
Stroke, Alzheimer s Disease
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingPhase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
Alzheimer s Disease
RecruitingObservational study
Speech and Language Interventions for Italian People With PPA
Primary Progressive Aphasia(PPA)
Not yet recruitingObservational study
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Virtual reality reaction time test in people with Alzheimer s Disease and Dementia, run by University of Vigo at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Virtual reality reaction time test (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.